Curated CRC research, accessible, accurate, actionable

The CRC Digest

Wednesday, October 07, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  AI-based blood test detects colorectal cancer and advanced adenomas using protein and miRNA biomarkers

  A prospective study of 3,569 participants validated an artificial intelligence algorithm that analyzes plasma samples to identify colorectal cancer and advanced adenomas, offering a potential non-invasive screening alternative. (Clinical and Translational Gastroenterology)

• ▪ SCREENING

  Computer-aided detection improves adenoma detection during surveillance colonoscopy in Italian screening program

  A randomized controlled trial of 914 patients aged 50-74 undergoing post-polypectomy surveillance found that AI-assisted colonoscopy increased adenoma detection compared to standard colonoscopy. (Digestive and Liver Disease)

• ♥ LIVING WITH CRC

  Measurable residual disease testing enables earlier recurrence detection and personalized surveillance after treatment

  MRD testing using circulating tumor DNA can identify patients at higher risk of recurrence before disease becomes clinically apparent, potentially guiding adjuvant treatment decisions and reducing uncertainty during post-treatment surveillance. (The ASCO Post)

• ▸ TREATMENT

  Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer

  A case report describes a 26-year-old woman with microsatellite-stable, BRAF V600E-mutant stage IVC disease who achieved complete remission with first-line immunotherapy and targeted therapy combination, without cytotoxic chemotherapy. (Anticancer Drugs)

This week's research spans advances in non-invasive screening technologies, biomarker-guided surveillance, and targeted therapies for molecularly defined subsets of colorectal cancer.